Credit: New Africa/Adobe Stock
Over 40% of people in the U.S. are living with obesity and over 11% have Type 2 Diabetes. Metabolic disease is a public health crisis that is driving unsustainable health care spending. Diabetes care alone now exceeds $410 billion annually, with much of that burden shouldered by employers, who cover direct costs like medication and treatment, and individuals who face expensive co-pays and rising health insurance premiums.
GLP-1s have introduced both opportunity and complexity to this already convoluted landscape. While many health plans and employers are still reeling from sticker shock, the potential of this promising new class of drugs to combat obesity by inducing weight loss is undeniable.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
